Core Insights - VivoSim Labs, Inc. has validated its NAMkind™ liver and intestine models for predicting toxicity and side effect profiles of antibody drug conjugates (ADCs) [1][2] Group 1: ADC Toxicity and Validation - The NAMkind™ models are positioned as essential tools to differentiate anticancer activity from unwanted cytotoxicity in ADCs, which are widely used in oncology [2] - Testing of approved ADC therapies in NAMkind™ models shows a strong correlation with clinical results, effectively identifying liver toxicity in drugs like gemtuzumab ozogomicin and low liver toxicity in enfortumab vedotin [3] - The NAMkind™ intestine models can detect differential effects on epithelial cells, providing insights into the overall impact of ADCs on intestinal health [4] Group 2: Industry Impact and Adoption - The models are expected to enhance the success rate of ADC candidates in clinical settings by allowing partners to screen out toxicities during early development stages [5] - VivoSim's NAMkind models are recognized as cutting-edge in the field, with services now available in the US, Europe, Korea, and China, indicating a scaling capacity to meet global demand [6] - The anticipated shift towards non-animal testing methods following FDA announcements is expected to accelerate the adoption of human tissue models in drug development [7]

Core Insights - VivoSim Labs, Inc. has appointed Dr. Arumugham Raghunathan as Vice President of Global Sales to enhance commercial growth and partnerships in the biopharma sector, particularly focusing on liver and gastrointestinal toxicity solutions [1][2][3] Company Overview - VivoSim Labs, Inc. specializes in next-generation New Approach Methodologies (NAMs) for preclinical safety, utilizing three-dimensional human tissue models for liver and intestinal toxicology [7] - The company is based in San Diego, California, and aims to accelerate the adoption of human tissue models following regulatory changes favoring non-animal testing methods [7] Leadership and Strategy - Dr. Raghunathan is recognized for his ability to build consultative relationships and guide clients from pilot studies to large-scale deployments, particularly in safety assessment and decision-making [2][3] - Under his leadership, VivoSim will focus on enhancing customer engagement and delivering solutions that provide clearer insights into drug candidate toxicity, thereby improving decision-making processes [4][5] Market Demand and Services - There is a growing demand for human-relevant toxicity prediction tools, especially in the Boston area and along the East Coast, as drug development timelines shorten and modalities diversify [5] - VivoSim's services are designed to support various stakeholders, including biotech startups, large pharmaceutical companies, and academic institutions, by providing insights into liver and GI toxicity [6]

Core Insights - VivoSim Labs, Inc. is presenting new data on its NAMkind™ liver and intestine models at the Society of Toxicology meeting, demonstrating their ability to predict toxicity and side effects of antibody drug conjugates (ADCs) [1][4] Group 1: Company Overview - VivoSim Labs, Inc. specializes in next-generation New Approach Methodologies (NAMs) for preclinical safety, focusing on testing drugs in 3D human tissue models of the liver and intestine [7] - The company operates from San Diego, CA, and is expanding its services globally, including in the US, Europe, Korea, and China [6][7] Group 2: Product and Technology - The NAMkind™ models can provide insights into target engagement, premature linker cleavage, and bystander effects in complex human cell models [3] - Testing of approved ADC therapies in NAMkind™ models has shown a close correlation with clinical results, particularly regarding liver toxicity and intestinal side effects [4][5] Group 3: Market Potential and Demand - With hundreds of ADCs in development globally, the NAMkind™ models are positioned as a powerful tool to mitigate off-target toxicity and enhance drug candidate selection [2] - The FDA's announcement to refine animal testing requirements in favor of NAM methods is expected to accelerate the adoption of these human tissue models [7]

Core Insights - VivoSim Labs has appointed JCBio for Korea and Tekon Biotech for China to distribute its NAMKind™ toxicology services, enhancing its commercial presence in the Asia-Pacific region [1][12] - The demand for human-relevant toxicology is increasing as drug developers seek faster and more reliable preclinical safety assessments [2][11] Distribution Agreements - JCBio will facilitate the deployment of NAMKind™ services in Korea, providing local coordination and scientific engagement to streamline evaluations [9][8] - Tekon Biotech aims to introduce VivoSim's NAMKind™ platforms to the Greater China market, addressing the need for accurate preclinical safety data [4][5] Market Dynamics - The in-vitro toxicology testing market in China is projected to grow from approximately $1.05 billion in 2023 to $2.26 billion by 2030, driven by increased R&D investment and evolving regulatory standards [5] - The pharmaceutical industry in China is shifting from generic manufacturing to innovative drug development, increasing the demand for predictive tools to mitigate late-stage clinical failures [7] Regulatory Alignment - Korea's regulatory body, MFDS, is aligning with the U.S. FDA's momentum towards adopting NAM-based evidence, which is expected to accelerate the acceptance of new toxicology techniques [3] Technological Advantages - VivoSim's NAMKind™ platform offers a modern approach to toxicology, designed to save time, reduce risk, and cut costs by providing human-based screening insights [10][12] - The platform is capable of delivering actionable results with a targeted 30-day turnaround time per compound, making it practical for both small and large molecules [12]

Core Insights - VivoSim Labs, Inc. has appointed Dr. Amar Sethi as Chief Scientific Officer to enhance its scientific strategy and capabilities in drug testing and toxicology [1][5] Company Overview - VivoSim Labs is a pharmaceutical and biotechnology services company focused on testing drugs in three-dimensional human tissue models, specifically for liver and intestine [6] - The company anticipates increased adoption of its human tissue models following FDA's announcement to refine animal testing requirements in favor of non-animal methods [6] Leadership Appointment - Dr. Amar Sethi brings three decades of experience in pharmaceutical drug development, CRO leadership, and diagnostic innovation [2] - His previous roles include leading global clinical programs and developing FDA-qualified biomarker platforms, contributing to significant business growth [4] Strategic Focus - Dr. Sethi will lead initiatives in toxicology, translational models, and bioanalytics, aiming to enhance multi-parametric toxicity prediction using human-relevant systems [3] - The company aims to integrate advanced 3D biology with AI-driven analytics to provide earlier decision-ready insights for sponsors [5] Market Positioning - VivoSim Labs is positioned to be a preferred scientific partner as the industry increasingly adopts 3D NAM systems for drug development [5]

Core Points - Charles River Laboratories announced the resignation of CFO Flavia H. Pease, effective September 29, 2025, and appointed Michael G. Knell as interim CFO while a search for a permanent successor is conducted [1][2] - The company reaffirmed its financial guidance for 2025, including revenue and non-GAAP earnings per share, based on its current outlook for third-quarter performance [3] Management Transition - Flavia H. Pease contributed significantly during her three years at the company, helping to navigate challenging demand environments and optimize cost structures [2] - Michael G. Knell, who has been with the company since 2017, is expected to lead the finance organization effectively during the interim period [2] Financial Guidance - The company maintains its previously provided financial guidance for 2025, indicating confidence in its revenue and earnings projections [3]

Core Insights - VivoSim Labs has appointed Tony Lialin as Chief Commercial Officer to enhance its AI-enabled NAMkind™ liver and intestine toxicology services in a growing market [1][2] - The global market for liver and gastrointestinal in-vitro models and toxicology services generated $641 million in revenue in 2024, with services accounting for 53.1% of this revenue [3] - The U.S. market for liver toxicology models and services is valued at $325 million, representing 50.8% of the global market [3] Market Opportunity - The global in vitro liver model market is experiencing a growth rate of 5.9% CAGR from 2020 to 2024, indicating increasing adoption of 3D human-relevant systems [3] - Regulatory changes, such as the FDA Modernization Act 2.0, are driving the adoption of non-animal methodologies, which supports the use of human-relevant in vitro models for ADME and toxicology [4] Technology and Services - VivoSim Labs utilizes AI to enhance the analysis of multi-parametric toxicity signatures in liver and intestinal organoid assays, improving the reliability of dose-response analyses [5] - The company's NAMkind™ models are designed to provide critical toxicology insights earlier in the drug development process, aiming to streamline pre-IND decision-making [6] Company Overview - VivoSim Labs focuses on testing drugs and drug candidates using 3D human tissue models of the liver and intestine, offering insights through its NAM models [7] - The company anticipates increased adoption of its human tissue models following recent FDA announcements aimed at refining animal testing requirements [7]